TN2011000295A1 - Glucagon analogues - Google Patents

Glucagon analogues

Info

Publication number: TN2011000295A1
Authority: TN; Tunisia
Prior art keywords: methods; peptides; glucagon; glucagon analogues; glp
Prior art date: 2008-12-15

Application number

TN2011000295A

Other languages

English (en)

Inventor

Eddi Meier

Ditte Riber

Marie Skovgaard

Bjarne Due Larsen

Jens Rosengren Daugaard

Original Assignee

Zealand Pharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-15

Filing date

2011-06-10

Publication date

2012-12-17

2011-06-10 Application filed by Zealand Pharma As filed Critical Zealand Pharma As

2012-12-17 Publication of TN2011000295A1 publication Critical patent/TN2011000295A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Genetics & Genomics (AREA)
Endocrinology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Obesity (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Toxicology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Microbiology (AREA)
Child & Adolescent Psychology (AREA)
Neurosurgery (AREA)

TN2011000295A 2008-12-15 2011-06-10 Glucagon analogues TN2011000295A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/GB2008/004121 WO2010070251A1 (fr)	2008-12-15	2008-12-15	Analogues du glucagon

Publications (1)

Publication Number	Publication Date
TN2011000295A1 true TN2011000295A1 (en)	2012-12-17

Family

ID=40428061

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2011000295A TN2011000295A1 (en)	2008-12-15	2011-06-10	Glucagon analogues

Country Status (19)

Country	Link
US (2)	US8685919B2 (fr)
EP (2)	EP2799447B1 (fr)
JP (1)	JP5635529B2 (fr)
KR (2)	KR20150116912A (fr)
CN (1)	CN102282167B (fr)
AP (1)	AP2011005774A0 (fr)
AU (1)	AU2008365555B2 (fr)
BR (1)	BRPI0823378A2 (fr)
CA (1)	CA2747109A1 (fr)
EA (1)	EA020537B1 (fr)
HK (1)	HK1203531A1 (fr)
IL (1)	IL213477A0 (fr)
MA (1)	MA32970B1 (fr)
MX (1)	MX2011006313A (fr)
MY (1)	MY160219A (fr)
SG (1)	SG172170A1 (fr)
TN (1)	TN2011000295A1 (fr)
UA (1)	UA104605C2 (fr)
WO (1)	WO2010070251A1 (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2607150C (fr)	2005-05-04	2014-08-05	Bjarne Due Larsen	Analogues du glp-2 (glucagon-like-peptide-2)
WO2008056155A1 (fr)	2006-11-08	2008-05-15	Zealand Pharma A/S	Analogues sélectifs du peptide 2 de type glucagon (glp-2)
MX2011006314A (es)	2008-12-15	2011-09-22	Zealand Pharma As	Analogos de glucagon.
EA020596B1 (ru)	2008-12-15	2014-12-30	Зилэнд Фарма А/С	Аналоги глюкагона
CA2747155A1 (fr)	2008-12-15	2010-06-24	Zealand Pharma A/S	Analogues du glucagon
AU2010272944B2 (en) *	2009-07-13	2015-11-19	Zealand Pharma A/S	Acylated glucagon analogues
PH12012502121A1 (en)	2010-04-27	2019-07-10	Zealand Pharma As	Peptide conjugates of glp-1 receptor agonists and gastrin and their use
AR081975A1 (es)	2010-06-23	2012-10-31	Zealand Pharma As	Analogos de glucagon
MA34383B1 (fr) *	2010-06-24	2013-07-03	Zealand Pharma As	Analogues de glucagon
SG192038A1 (en) *	2011-01-20	2013-08-30	Zealand Pharma As	Combination of acylated glucagon analogues with insulin analogues
EP2758426B1 (fr) *	2011-09-23	2019-08-07	Novo Nordisk A/S	Nouveaux analogues de glucagon
CA2853884A1 (fr)	2011-11-03	2013-05-10	Zealand Pharma A/S	Conjugues de peptide agoniste du recepteur du glp-1 et de gastrine
AR090937A1 (es)	2012-05-03	2014-12-17	Zealand Pharma As	Compuestos agonista duales de gip-glp-1 y metodos para usarlos
CN104540850B (zh) *	2012-05-03	2018-05-18	西兰制药公司	胰高血糖素样肽2(glp-2)类似物
EP2664374A1 (fr) *	2012-05-15	2013-11-20	F. Hoffmann-La Roche AG	Dérivés de dipeptide d'acide lysine-glutamique
EA201590011A1 (ru)	2012-06-14	2015-05-29	Санофи	Пептидные аналоги эксендина-4
TWI642682B (zh)	2012-07-23	2018-12-01	丹麥商西蘭製藥公司	升糖素類似物
TWI608013B (zh) *	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
WO2014049610A2 (fr)	2012-09-26	2014-04-03	Cadila Healthcare Limited	Peptides en tant que triples agonistes des récepteurs de gip, glp-1 et glucagon
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
MA38276B1 (fr)	2012-12-21	2018-03-30	Sanofi Sa	Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif.
SG11201506885UA (en)	2013-03-21	2015-09-29	Sanofi Aventis Deutschland	Synthesis of cyclic imide containing peptide products
US10087221B2 (en)	2013-03-21	2018-10-02	Sanofi-Aventis Deutschland Gmbh	Synthesis of hydantoin containing peptide products
WO2014161835A1 (fr)	2013-04-03	2014-10-09	Sanofi	Protéines de régulation de la glycémie modifiées ayant un profil d'activité pharmacologique modifié, et leur préparation
MX362275B (es)	2013-04-18	2019-01-10	Novo Nordisk As	Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
GB201315335D0 (en) *	2013-08-29	2013-10-09	Of Singapore	Amino diacids containing peptide modifiers
DK3057984T3 (en)	2013-10-17	2018-10-08	Zealand Pharma As	ACYLED GLUCAGON ANALOGS
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
TWI670281B (zh) *	2013-11-06	2019-09-01	西蘭製藥公司	Ｇｉｐ－ｇｌｐ－１雙重促效劑化合物及方法
AU2014345570B2 (en)	2013-11-06	2019-01-24	Zealand Pharma A/S	Glucagon-GLP-1-GIP triple agonist compounds
WO2015086729A1 (fr)	2013-12-13	2015-06-18	Sanofi	Agonistes mixtes des récepteurs glp-1/gip
EP3080149A1 (fr)	2013-12-13	2016-10-19	Sanofi	Agonistes mixtes des récepteurs du glp-1/glucagon
TW201609795A (zh)	2013-12-13	2016-03-16	賽諾菲公司	作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086731A1 (fr)	2013-12-13	2015-06-18	Sanofi	Analogues peptidiques de l'exendine-4 en tant qu'agonistes mixtes des récepteurs glp-1/glucagon
TW201609796A (zh)	2013-12-13	2016-03-16	賽諾菲公司	非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
EP3151852A1 (fr)	2014-06-04	2017-04-12	Novo Nordisk A/S	Co-agonistes de récepteur du glucagon/glp-1 à usage médical
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
JP6898231B6 (ja)	2014-10-29	2021-07-28	ジーランドファーマアクティーゼルスカブ	Ｇｉｐアゴニスト化合物及び方法
EP3673900B1 (fr)	2015-02-17	2025-06-25	Amphastar Pharmaceuticals, Inc.	Formulation de poudre nasale pour le traitement de l'hypoglycémie
TWI748945B (zh) *	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
CA2979950A1 (fr)	2015-03-18	2016-09-22	Zealand Pharma A/S	Analogues d'amyline
WO2016168388A2 (fr)	2015-04-14	2016-10-20	Palatin Technologies, Inc.	Thérapies pour l'obésité, le diabète et indications associées
RU2735762C2 (ru)	2015-04-16	2020-11-06	Зилэнд Фарма А/С	Ацилированный аналог глюкагона, его применение и способы получения
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (fr)	2015-06-12	2016-12-15	Sanofi	Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip
WO2016198628A1 (fr)	2015-06-12	2016-12-15	Sanofi	Dérivés d'exendine-4 non-acylée comme agonistes doubles du récepteur glp -1/glucagon
AR105284A1 (es)	2015-07-10	2017-09-20	Sanofi Sa	Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
WO2018024653A1 (fr)	2016-08-05	2018-02-08	Boehringer Ingelheim International Gmbh	Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre)
US10071140B2 (en)	2016-09-09	2018-09-11	Zealand Pharma A/S	Amylin analogues
AR110299A1 (es)	2016-12-02	2019-03-13	Sanofi Sa	Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
JP6563614B1 (ja)	2016-12-09	2019-08-21	ジーランド・ファーマ・ア／エス	アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト
WO2018103868A1 (fr) *	2016-12-09	2018-06-14	Zealand Pharma A/S	Agonistes doubles de glp-1/glp-2 acylés
CN118526577A (zh)	2017-06-16	2024-08-23	西兰制药公司	用于施用胰高血糖素样肽2（glp-2）类似物的剂量方案
CA3087827A1 (fr)	2018-02-02	2019-08-08	Boehringer Ingelheim International Gmbh	Derives d'oxadiazolopyridine a substitution heterocyclyle utilises en tant qu'inhibiteurs de la ghreline o-acyltransferase (goat)
KR20200116978A (ko)	2018-02-02	2020-10-13	베링거 인겔하임 인터내셔날 게엠베하	그렐린 o-아실 트랜스퍼라제(goat) 억제제로서의 벤질-치환된, (피리딘-3-일)메틸-치환된 또는 (피리딘-4-일)메틸-치환된 옥사디아졸로피리딘 유도체
EP3746449B1 (fr)	2018-02-02	2022-03-30	Boehringer Ingelheim International GmbH	Dérivés d'oxadiazolopyridine à substitution pyrazole et indazole destinés à être utilisés en tant qu'inhibiteurs de la ghréline o-acyl transférase (goat)
BR112020014436A2 (pt)	2018-02-02	2020-12-01	Boehringer Ingelheim International Gmbh	derivados de triazolopirimidina, composição farmacêutica e seus usos como inibidores de grelina o-acil transferase (goat)
CA3096493A1 (fr) *	2018-04-10	2019-10-17	Sanofi-Aventis Deutschland Gmbh	Procede de clivage de peptides lies a une phase solide a partir de la phase solide
US20220153853A1 (en)	2018-12-21	2022-05-19	Jiangsu Hengrui Medicine Co., Ltd.	Bispecific protein
TWI771669B (zh)	2019-04-26	2022-07-21	美商美國禮來大藥廠	製備穩定胜肽調配物之方法
WO2021094259A1 (fr)	2019-11-11	2021-05-20	Boehringer Ingelheim International Gmbh	Agonistes du récepteur npy2
KR20230045088A (ko)	2020-08-07	2023-04-04	베링거 인겔하임 인터내셔날 게엠베하	가용성 npy2 수용체 작용제

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ202757A (en)	1981-12-23	1985-11-08	Novo Industri As	Peptides and medicaments
IL128332A0 (en)	1996-08-30	2000-01-31	Novo Nordisk As	GLP-1 derivatives
WO1998011126A1 (fr)	1996-09-09	1998-03-19	Zealand Pharmaceuticals A/S	Promedicaments peptidiques contenant une sequence de liaison alpha-hydroxyacide
AU723268B2 (en)	1996-09-09	2000-08-24	Zealand Pharma A/S	Improved solid-phase peptide synthesis and agent for use in such synthesis
ES2294822T3 (es)	1997-11-14	2008-04-01	Amylin Pharmaceuticals, Inc.	Compuestos novedosos de agonistas de exendina.
JP4394279B2 (ja)	1998-03-09	2010-01-06	ジーランドファーマアクティーゼルスカブ	酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
JP3702181B2 (ja)	1998-12-07	2005-10-05	ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス	Ｇｌｐ−１の類似体
US6451987B1 (en)	1999-03-15	2002-09-17	Novo Nordisk A/S	Ion exchange chromatography of proteins and peptides
EP1956000B1 (fr)	1999-03-17	2016-10-05	Novo Nordisk A/S	Agents d'acylation utilisés dans l'acylation de peptides
EP1076066A1 (fr)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides abaissant le taux de glucose sanguin
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
WO2003053460A1 (fr)	2001-12-19	2003-07-03	Eli Lilly And Company	Compositions cristallines pour reguler la glycemie
SK2432004A3 (sk)	2001-12-20	2005-04-01	Eli Lilly And Company	Inzulínová zlúčenina s protrahovaným účinkom
GB0300571D0 (en)	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
AU2004234345A1 (en)	2003-04-29	2004-11-11	Eli Lilly And Company	Insulin analogs having protracted time action
JP2008543816A (ja)	2005-06-13	2008-12-04	インペリアルイノベーションズリミテッド	新規化合物および該化合物が摂食行動に及ぼす効果
WO2007024899A2 (fr)	2005-08-23	2007-03-01	The General Hospital Corporation	Utilisation de glp-1, derives de glp-1 ou fragments de glp-1 aux fins de regeneration de la peau ou stimulation de la croissance des poils ou de traitement des diabetes
CN101534846B (zh) *	2005-11-07	2014-11-05	印第安纳大学研究及科技有限公司	显示生理学溶解性和稳定性的胰高血糖素类似物
US8343914B2 (en)	2006-01-06	2013-01-01	Case Western Reserve University	Fibrillation resistant proteins
CN101389648B (zh)	2006-02-22	2013-07-17	默沙东公司	肽胃泌酸调节素衍生物
CN101622276B (zh)	2006-07-18	2015-04-22	赛诺菲-安万特	用于治疗癌症的抗epha2的拮抗抗体
ES2554773T3 (es)	2006-10-04	2015-12-23	Case Western Reserve University	Insulina y análogos de la insulina resistentes a la fibrilación
TWI428346B (zh)	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
CA2677932A1 (fr) *	2007-02-15	2008-08-21	Indiana University Research And Technology Corporation	Co-agonistes des recepteurs du glucagon/glp-1
EP2025684A1 (fr)	2007-08-15	2009-02-18	Zealand Pharma A/S	Analogues du glucagon
JP5385266B2 (ja)	2007-06-15	2014-01-08	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
MX338336B (es)	2007-11-20	2016-04-07	Ambrx Inc	Polipeptidos de insulina modificados y sus usos.
DE102008003566A1 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
KR20100111683A (ko)	2008-01-09	2010-10-15	사노피-아벤티스 도이칠란트 게엠베하	극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
NZ586590A (en)	2008-01-09	2012-06-29	Sanofi Aventis Deutschland	Insulin analogues or derivatives having an extremely delayed time-action profile
DE102008003568A1 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
US8993516B2 (en)	2008-04-14	2015-03-31	Case Western Reserve University	Meal-time insulin analogues of enhanced stability
KR20110021758A (ko)	2008-04-22	2011-03-04	케이스 웨스턴 리저브 유니버시티	이형체-특이적 인슐린 유사체
TWI451876B (zh)	2008-06-13	2014-09-11	Lilly Co Eli	聚乙二醇化之離脯胰島素化合物
CL2009001424A1 (es)	2008-06-17	2010-04-30	Univ Indiana Res & Tech Corp	Peptido tipo glucagon; dimero que comprende dos de dichos peptidos; composicion farmaceutica que lo comprende; y su uso para tratar diabetes o inducir perdida de peso.
AU2009260301B2 (en)	2008-06-17	2015-09-03	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
PL219335B1 (pl)	2008-07-04	2015-04-30	Inst Biotechnologii I Antybiotyków	Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
KR20110061552A (ko)	2008-07-31	2011-06-09	케이스 웨스턴 리저브 유니버시티	할로겐 안정화된 인슐린
EA020596B1 (ru)	2008-12-15	2014-12-30	Зилэнд Фарма А/С	Аналоги глюкагона
CA2747155A1 (fr)	2008-12-15	2010-06-24	Zealand Pharma A/S	Analogues du glucagon
MX2011006314A (es)	2008-12-15	2011-09-22	Zealand Pharma As	Analogos de glucagon.
AU2009335715B2 (en)	2008-12-19	2016-09-15	Indiana University Research And Technology Corporation	Amide-based insulin prodrugs
WO2010080606A1 (fr)	2008-12-19	2010-07-15	Indiana University Research And Technology Corporation	Analogues d'insuline
CN101519446A (zh)	2009-03-31	2009-09-02	上海一就生物医药有限公司	一种重组人胰岛素及其类似物的制备方法
AU2010272944B2 (en)	2009-07-13	2015-11-19	Zealand Pharma A/S	Acylated glucagon analogues
AU2011206979B2 (en)	2010-01-20	2015-09-10	Zealand Pharma A/S	Treatment of cardiac conditions
AR081975A1 (es)	2010-06-23	2012-10-31	Zealand Pharma As	Analogos de glucagon
MA34383B1 (fr)	2010-06-24	2013-07-03	Zealand Pharma As	Analogues de glucagon
SG192038A1 (en)	2011-01-20	2013-08-30	Zealand Pharma As	Combination of acylated glucagon analogues with insulin analogues

2008
- 2008-12-15 WO PCT/GB2008/004121 patent/WO2010070251A1/fr not_active Ceased
- 2008-12-15 MY MYPI2011002751A patent/MY160219A/en unknown
- 2008-12-15 KR KR1020157027018A patent/KR20150116912A/ko not_active Ceased
- 2008-12-15 US US13/139,493 patent/US8685919B2/en not_active Expired - Fee Related
- 2008-12-15 EP EP14175826.8A patent/EP2799447B1/fr active Active
- 2008-12-15 MX MX2011006313A patent/MX2011006313A/es active IP Right Grant
- 2008-12-15 EA EA201190047A patent/EA020537B1/ru not_active IP Right Cessation
- 2008-12-15 AU AU2008365555A patent/AU2008365555B2/en not_active Ceased
- 2008-12-15 KR KR1020117016184A patent/KR20110126589A/ko not_active Ceased
- 2008-12-15 AP AP2011005774A patent/AP2011005774A0/xx unknown
- 2008-12-15 SG SG2011043700A patent/SG172170A1/en unknown
- 2008-12-15 EP EP08875670A patent/EP2370459A1/fr not_active Withdrawn
- 2008-12-15 UA UAA201108817A patent/UA104605C2/uk unknown
- 2008-12-15 BR BRPI0823378A patent/BRPI0823378A2/pt not_active IP Right Cessation
- 2008-12-15 JP JP2011540187A patent/JP5635529B2/ja not_active Expired - Fee Related
- 2008-12-15 CN CN200880132682.4A patent/CN102282167B/zh not_active Expired - Fee Related
- 2008-12-15 CA CA2747109A patent/CA2747109A1/fr not_active Abandoned
- 2008-12-15 MA MA34020A patent/MA32970B1/fr unknown
2011
- 2011-06-10 TN TN2011000295A patent/TN2011000295A1/fr unknown
- 2011-06-12 IL IL213477A patent/IL213477A0/en unknown
2014
- 2014-03-03 US US14/195,533 patent/US20150080295A1/en not_active Abandoned
2015
- 2015-05-05 HK HK15104289.5A patent/HK1203531A1/en unknown

Also Published As

Publication number	Publication date
AU2008365555A1 (en)	2011-07-21
JP5635529B2 (ja)	2014-12-03
MY160219A (en)	2017-02-28
AP2011005774A0 (en)	2011-06-30
CN102282167A (zh)	2011-12-14
EA020537B1 (ru)	2014-11-28
KR20150116912A (ko)	2015-10-16
US8685919B2 (en)	2014-04-01
EP2370459A1 (fr)	2011-10-05
CN102282167B (zh)	2014-08-13
MX2011006313A (es)	2011-09-27
CA2747109A1 (fr)	2010-06-24
JP2012511899A (ja)	2012-05-31
EP2799447A2 (fr)	2014-11-05
HK1203531A1 (en)	2015-10-30
EA201190047A1 (ru)	2012-02-28
MA32970B1 (fr)	2012-01-02
AU2008365555B2 (en)	2016-01-14
EP2799447A3 (fr)	2014-12-31
WO2010070251A1 (fr)	2010-06-24
EP2799447B1 (fr)	2016-11-23
UA104605C2 (uk)	2014-02-25
US20150080295A1 (en)	2015-03-19
KR20110126589A (ko)	2011-11-23
BRPI0823378A2 (pt)	2019-09-24
US20110286982A1 (en)	2011-11-24
IL213477A0 (en)	2011-07-31
SG172170A1 (en)	2011-07-28

Publication	Publication Date	Title
MX2011006320A (es)	2011-09-22	Analogos de glucagon.
TN2011000295A1 (en)	2012-12-17	Glucagon analogues
MX2011006314A (es)	2011-09-22	Analogos de glucagon.
MX2011006315A (es)	2011-09-22	Analogos de glucagon.
MY188182A (en)	2021-11-24	Acylated glucagon analogues
TN2012000560A1 (en)	2014-04-01	Glucagon analogues
TN2012000567A1 (en)	2014-04-01	Glucagon analogues
DK2158214T3 (da)	2011-12-05	Glukagonanaloger
HK1200369A1 (en)	2015-10-09	Glucagon analogues
WO2014041195A8 (fr)	2015-02-26	Analogues du glucagon
WO2015055802A3 (fr)	2016-01-07	Analogues du glucagon
MY176022A (en)	2020-07-21	Acylated glucagon analogues
MX2017012864A (es)	2018-06-12	Analogo acilado del glucagon.
TN2011000667A1 (en)	2013-05-24	Acylated glucagon analogues
CO6382136A2 (es)	2012-02-15	Análogos de glucagón